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ABSTRACT
Objective: The aim of this study was to compare the dynamic distribution of fluorodeoxyglucose (FDG)
in malignant and in infectious lesions. Methods: The dynamic distribution of FDG was studied in Rowett
nude (RNU) rats with a LS174T carcinoma xenograft in the left front leg and an Escherichia coli–induced
focal infection in the right front leg. In 5 rats, dynamic FDG-PET was performed (27 frames of 6–15 min-
utes) up to 4 hours after injection of 11 MBq 18FDG. The mean FDG uptake (SUV) was calculated and
plotted by using a region of interest (ROI) centered over both lesions. In groups of 6 rats, the biodistri-
bution of FDG was determined by counting dissected tissues at 1, 2, 3, and 4 hours after an injection of
11 MBq FDG. Means  the standard error of the mean (SEM) were calculated. Results: Dynamic positron
emission tomography (PET) visualized both the tumor and the infection. The ROI analysis showed that
FDG uptake in the infections was faster and higher, as compared to the tumor lesions. FDG uptake in
the tumor reached a standardized uptake value (SUV) of 0.8  0.3 at 60 minutes and in the infectious le-
sions a SUV of 1.6  0.2 at 45 minutes, both remaining constant until 4 hours postinjection (p.i.). In the
biodistribution study with ex vivo tissue counting, FDG had accumulated up to 1.1  0.1 %ID/g and
0.8  0.1 %ID/g at 1 hour in the tumor and infection, respectively, and remained constant until 4 hours
for both lesions without significantly different wash-out from the 2 lesions. The tumor/blood and ab-
scess/blood ratios increased with time to 57  17 and 48  14, respectively. Conclusion: Although in
this model differences in absolute FDG uptake and initial kinetics between tumor and infection were ob-
served, the wash-out rate of FDG from the lesions was similar over time. The retention of FDG in the in-
flammatory lesion indicated that dual time-point imaging does not necessarily resolve diagnostic pitfalls
for FDG-PET in oncology in order to discriminate between malignant tumorous and benign infectious le-
sions.
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INTRODUCTION
Fluorodeoxyglucose positron emission tomogra-
phy (FDG-PET) is a sensitive modality for the
diagnosis and staging of several types of malig-
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nancies.1 The accumulation of fluorodeoxyglu-
cose (FDG) is caused by increased glucose uti-
lization of tumor cells.2 It has been shown that
FDG also accumulates in inflammatory lesions.
Lesions with a high concentration of inflamma-
tory cells, such as granulocytes and activated
macrophages, show increased uptake and reten-
tion of FDG.3,4 High uptake of FDG in inflam-
matory lesions may, therefore, result in false-pos-
itive interpretations in patients with cancer, thus
decreasing specificity and positive predictive
value. The standardized uptake value (SUV) is
not always a valid tool to distinguish between ma-
lignant and benign lesions, owing to many con-
founding factors, such as elevated plasma glucose
level, differences in uptake period of FDG, and
partial-volume effect. Recent studies have shown
that FDG is better retained in malignant cells.
Nakamoto et al. reported, in a study with 47 pa-
tients with suspected pancreatic carcinoma, that
the retention index for malignant disease was sig-
nificantly greater than that of benign disease. The
addition of a later imaging time point could aid
in differentiating benign and malignant le-
sions.5–12
By means of multiple time-point imaging and
calculation of the SUV or lesion-to-blood ratios
on both time points, it may be possible to dis-
criminate between tumorous and infectious le-
sions. It has been reported that the SUV would
decrease over time in case of infection, but in-
crease or remain stable in case of malignancy.5–12
The aim of this study was to determine whether
there are differences in the kinetics of FDG up-
take between malignant and infectious lesions in
a rat model.
METHODS
Preparation of Animals
All animal experiments were approved by the lo-
cal animal welfare committee and performed in
accordance with their guidelines. In male Rowett
nude (RNU) rats (Charles River; Sulzfeld, Ger-
many), 6–8 weeks of age with an average weight
of 200 g, tumors were induced by a subcutaneous
injection of 2.5  106 LS174T cells in the left
front leg (1.25  107 cells/mL) 2 weeks prior to
FDG injection.
The human colorectal carcinoma cell line
LS174T was obtained from the American Type
Culture Collection (Rockville, MD). LS174T is
a rapidly growing, moderately to well-differenti-
ated human colorectal carcinoma cell line.
LS174T was cultured and maintained as a con-
fluent, growing cells on plastic in RPMI-1640
medium (GIBCO, BRL Life Science Technolo-
gies, Breda, The Netherlands), supplemented
with 10% fetal calf serum (FCS) (GIBCO), 
L-glutamine, penicillin (100 U/mL), and strep-
tomycin (100 g/mL) (GIBCO, BRL Life Sci-
ence Technologies).13 Before inoculation, tumor
cells were washed with 0.9% NaCl, disag-
gregated with 0.25% trypsin, and resuspended 
in complete medium to the appropriate concen-
tration.
After 2 weeks, when tumors were approxi-
mately 1–2 cm in diameter, a soft tissue infection
was induced in the right front leg by intramus-
cular injection of 0.2 mL Escherichia coli sus-
pension (1.4  1010 cfu/mL).
The next day, the rats were fasted for 4 hours
to avoid the influence of increased insulin and/or
serum glucose levels on FDG uptake14 and in-
jected with 11 MBq of FDG intravenously (i.v.)
(Tyco-Mallinckrodt Healthcare; Petten, The
Netherlands) through the tail vein.
FDG-PET
Five RNU rats were kept anasthesized by isoflu-
rane/nitrous oxide/oxygen inhalation. 3D PET
(ECAT-EXACT, Siemens/CTI; Knoxville, TN)
was performed immediately after FDG injection
for a continuous period of 4 hours (27 frames of
6–15 minutes). During this period, the tempera-
ture was kept constant by a controlled external
heat source to avoid temperature-dependent
changes of the FDG uptake in tumor and in-
flammation.
The data were reconstructed and corrected for
attenuation using the iterative ordered-subsets ex-
pectation-maximization (OSEM) algorithm. Im-
ages were analyzed quantitatively by drawing re-
gions of interests (ROIs) centered over the
infected tissue and the tumor without correction
for partial volume effects.
The mean amount of activity, expressed as the
SUV, was calculated.
Biodistribution
Groups of 6 rats were killed and dissected at 1,
2, 3, and 4 hours after FDG injection. Blood sam-
ples, abscess, and tumor were collected. The dis-
sected tissues were weighed, and the activity in
the samples was measured in a well-type gamma-
counter. To correct for radioactive decay, a 1%
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FDG standard was measured simultaneously. The
activity in samples was expressed as the per-
centage of injected dose per gram of tissue
(%ID/g). Abscess-to-blood, tumor-to-blood, and
tumor-to-abscess ratios were calculated for each
time point.
Statistical Analysis
All mean values are given as the mean  one
standard error of the mean (SEM). The data were
analyzed statistically using a paired, two-tailed t
test (GraphPad Instat 3.00 Win 95; San Diego,
CA)
RESULTS
Imaging
Coronal FDG-PET images up to 4 hours are
shown in Figure 1. Already at 10 minutes p.i.,
both the abscess and the tumor were visualized.
The visualization of both lesions improved with
time. Figure 2 shows the quantitative ROI anal-
ysis of the PET images. There is a fast accumu-
lation of activity in both lesions within the 1st
hour after injection, after which the uptake re-
mains stable during the next 3 hours. The increase
of the FDG uptake in the infection was signifi-
cantly faster in the abscess (maximal SUVmean
1.6  0.03%) reached at 45 minutes; slope,
0.008  0.002), as compared to the FDG uptake
in the tumor (maximal SUVmean of 0.8  0.3%
reached at 60 minutes; slope, 0.004  0.003)
(p  0.05). There was no washout of activity ob-
served in either of the lesions.
Biodistribution
The results of the biodistribution at 1 hour and 4
hours p.i. are summarized in Figure 3. FDG up-
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Figure 1. Coronal PET images of rats with subcutaneous (s.c.) tu-
mor in left front leg and an Escherichia coli abscess in right front
leg injected with 11 MBq 18FDG. Images were acquired immedi-
ately after injection at several time points up to 4 hours postinjec-
tion (p.i.) (abscess  open arrow, tumor  closed arrow).
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Figure 2. Data derived from ROI analysis of the PET im-
ages. Images were analyzed quantitatively by drawing re-
gions of interest over the infected tissue and the tumor. Mean
amount of activity (SUV) is represented. ROI, region of in-
terest; PET, positron emission tomography; SUV, standard-
ized uptake value.
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take in the tumor at 1 hour p.i. was 1.1  0.1
%ID/g and remained stable up to 4 hours. The
uptake of FDG in the abscess was 0.8  0.1
%ID/g and also remained stable at that level up
to 4 hours p.i. Figure 4 shows that there was a
similar increase of the abscess-to-blood and the
tumor-to-blood ratios. The tumor-to-blood and
abscess-to-blood ratio increased with time to
57  17 and 48  14, respectively. Tumor-to-ab-
scess ratios were constant.
DISCUSSION
A wide variety of tumor cells, as well as acti-
vated inflammatory cells, have an increased
metabolic activity. In malignant cells, increased
FDG uptake is caused by an increased glucose
metabolism. This results in an upregulation of
glucose transporters and glycolytic enzymes.
Cells involved in the host defense against infec-
tion (e.g., infiltrating neutrophic granulocytes and
tissue macrophages) have a high glucose metab-
olism and increased glucose uptake when acti-
vated by infection.3,4 These pathophysiological
features cause that both tumor lesions and in-
flammatory lesions are detected by FDG-PET.
The accumulation of FDG in inflammatory le-
sions during FDG-PET scanning could reduce the
accuracy of FDG-PET when used for staging or
restaging malignant disease. Uptake in inflam-
matory lesion could decrease specificity when
staging, and it may obscure tumor response upon
restaging.
The results of this study showed that there was
a difference in the kinetics of early FDG uptake
in the infection and in the tumor. FDG was taken
up faster in the infectious lesion than in the tu-
mor. However, at later time points, neither con-
tinuous accumulation in the tumors nor wash-out
from the infection was observed. This is in con-
trast with human studies, where it has been re-
ported that tumor uptake of FDG increases for
hours after injection. Hamberg et al. reported in
a study of 8 patients with stage III lung caner that
FDG uptake by tumor did not reach the maxi-
mum level within 5 hours after injection.15
Nakamoto et al.9 reported in a study with 47 pa-
tients with suspected pancreatic carcinoma that
the retention index for malignant disease was sig-
nificantly greater than that of benign disease.
Zuang et al. reported that addition of a later imag-
ing time point could aid in differentiating benign
and malignant lesions.5 The pathophysiological
explanation for different FDG uptake patterns
over time between inflammatory and malignant
lesions is based on differences in enzyme activ-
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Figure 3. Biodistribution data obtained at 1, 2, 3, and 4
hours after injection of 11 MBq FDG in rats with subcuta-
neous (s.c.) tumor in left front leg and Escherichia coli ab-
scess in right front leg. Results are presented as the per-
centage of injected dose per gram (%ID/g).
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Figure 4. Biodistribution data obtained at 1, 2, 3, and 4
hours after injection of 11 MBq FDG in rats with subcuta-
neous (s.c.) tumor in left front leg and Escherichia coli ab-
scess in right front leg, Abscess-to-blood, tumor-to-blood,
and tumor-to-abscess ratios were calculated for each time
point.
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ity in tumor cells and in activated leukocytes.
FDG is transported into cells by glucose-trans-
porter molecules (GLUT 1–5). The GLUT ex-
pression and its relation to FDG accumulation in
malignant tumors have been investigated in clin-
ical and experimental studies.16 Significantly el-
evated expression levels of GLUT-1 and GLUT-
3 are considered to be a factor contributing to the
accumulation of FDG in malignant tumors. To
our knowledge, the expression of GLUT recep-
tors in our tumor model has not been studied.
Mochizuki et al.16 showed, in an animal model,
a relation between FDG uptake and the expres-
sions of GLUTs. The GLUT-1 expression level
was significantly higher in the tumor lesion than
in the inflammatory lesion, which may explain
higher FDG accumulation in the tumor lesion. In
the cell, FDG is phosphorylated to FDG-6-phos-
phate by hexokinase (generally, type II). FDG-6-
phosphate cannot cross the cell membrane, while
dephosphorylation of FDG by glucose-6-phos-
phatase occurs relatively slowly.17 Thus, FDG-6-
phosphate is trapped in the cells. Many cancer
cells are reported to have low levels of glucose-
6-phosphatase.5 In contrast, mononuclear cells
express high levels of glucose-6-phosphatase.
Therefore, there might be a different ratio of
hexokinase/phosphatase activity between inflam-
matory and malignant cells, which may result in
enhanced wash-out of FDG from inflammatory
cells. The relatively high glucose-6-phosphatase
activity in inflammatory cells has been observed
in mononuclear cells, while in acute infection the
infiltrated cells are mainly granulocytes. This
may explain the differences between our study
(using an acute model of infection) and data in
literature.8 An interesting point for future studies
would be to investigate the FDG uptake with the
time of acute and chronic stage of infection.
CONCLUSIONS
This animal model showed initial differences be-
tween initial FDG uptake in tumor and acute in-
fection with stable FDG concentrations in both
lesions at later time points. FDG uptake and in-
tracellular processing is multifactorial (e.g., de-
pendent on vascularization, glucose transporters,
intracellular glycolytic enzyme patterns, gly-
colytic pathways, and hypoxia). Assessment of
FDG-kinetics offers a possibility to increase
specificity for the differentiation between tumor
and inflammation to avoid unjustified denomina-
tion of malignant lesions as benign, inflamma-
tory tissue changes.
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